In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Best of the Blog: IN VIVO, December 2008

Executive Summary

The best posts from the In Vivo Blog in December include: Is biotech running GSK? And the FDA's internal advisory meeting: what Avandia, Vioxx, Ketek, Elidel and Palladone have in common.

You may also be interested in...

Regulatory Briefings: FDA's "Internal Advisory Committees"

When FDA reviewers need help on a tricky regulatory question, they get advice from top-level officials at an internal meeting called a regulatory briefing. Many sponsors don't even know they exist. But at a time of change in review procedures and staff, companies need to learn how FDA's "internal advisory committees" work.

GSK/Actelion: Phase III Value Is in the Eye of the Beholder

GSK paid a very large upfront fee ($148mm) for access to Actelion's Phase III insomnia candidate almorexant, but still some were disappointed; the Big Pharma is only paying 40% of the costs of the Phase III program. The truth is that even late-stage primary care assets--especially those with novel mechanisms of action--are under intense regulatory scrutiny and licensors are having to take on more risk.

GlaxoSmithKline Breaks Out of Its Small-Molecule Mind-Set

Following similar moves by many of its Big Pharma peers, GSK is buying into large molecules, big time. In December 2006, it paid $454 million in cash for next-generation antibody specialist Domantis. Later that month, the pharmaceutical firm committed over $2 billion in up-fronts, milestones, and equity for an antibody program from Genmab AS. For investors in privately held Domantis, whose most advanced drug candidate is preclinical, the acquisition was a much earlier than-anticipated exit.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts